MedTrace Logo

Glucose-dependent Insulinotropic Polypeptide - New Role as Blood Glucose Stabilizer?

NCT01048268 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2015-07-14

No results posted yet for this study

Summary

The purpose of this study is to determine whether glucose-dependent insulinotropic polypeptide (GIP) has a stabilizing function on the blood glucose

Conditions

Interventions

DRUG

glucose-dependent insulinotropic polypeptide

For the first 20 min of the experiment the volunteers will receive GIP at 4 pmol/kg body weight. For the following 40 minutes the volunteers will receive 2 pmol/kg body weight

DRUG

Placebo

copy GIP infusion rates

Sponsors & Collaborators

  • University Hospital, Gentofte, Copenhagen

    lead OTHER

Principal Investigators

  • Mikkel Christensen, MD · Bispebjerg Hospital, Copenhagen

  • Filip K Knop, MD PhD · Diabetes Research Division, Department of Internal Medicine F, Gentofte Hospital, University of Copenhagen

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-12-31
Primary Completion
2014-04-30
Completion
2014-04-30

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01048268 on ClinicalTrials.gov